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 Abstract 
This study aimed at evaluating the effect of high glucose on the expression of 
extracellular matrix (ECM) protein Matrilin-2 and the mechanism underlying this effect 
by using a mouse mesangial cell line. Mouse mesangial cells (MMCs) were cultured 
in media containing normal (5mM D-glucose) or high concentrations of glucose 
(30mM D-glucose). The expression of Matrilin-2 was assessed by either RT-PCR or 
western blot. Additionally, transforming growth factor beta 1 (TGF-β1) inhibitors and 
TGF-β1 were used to determine whether glucose-regulated Matrilin-2 expression was 
mediated by the TGF-β1/Smad3 signaling pathway. Our data demonstrated that 
Matrilin-2 expression was markedly induced by high glucose and TGF-β1. High 
glucose-induced Matrilin-2 expression was inhibited by TGF-β1/Smad3 inhibitors, 
indicating that Matrilin-2 was markedly induced by high glucose and this induction was 
mediated by the TGF-β1/Smad3 pathway. Taken together, our results showed that 
high-glucose-induced Matrilin-2 expression that was mediated by the TGF-β1/Smad3 
signaling pathway might play a role in Diabetic nephropathy (DN) pathogenesis and 
our finding provided a potential diagnostic and/or therapeutic target for DN. 
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1. Introduction 
   Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and one 
of the most significant long-term complications in terms of morbidity and mortality for 
individual patients with diabetes. Major typical morphological changes are the 
progressive accumulation of extracellular matrix (ECM) proteins in mesangial 
interstitial space to lead to glomerular and tubular basement membrane thickening 
and increase of mesangial matrix, ultimately resulting in glomerulosclerosis and 
tubulointerstitial fibrosis. ECM is a potential protein source of diagnostic biomarkers 
for renal fibrosis [1, 2], and among a large number of ECM proteins, Matrilin is a novel 
filamentous-forming adapter protein family, which can form collagen-dependent and 
-independent network of extracellular matrix [3-5]. Matrilin-2 is the largest member of 
the Matrilin family that shares von Willebrand factor A (vWFA) domains, epithelial 
growth factor (EGF) like repeats, and a series of heptad repeats at their C-terminal 
coiled-coil domain[6, 7]. Unlike other family members whose expression is limited to 
skeletal tissues, Matrilin-2 is found heterogeneously distributed in connective tissues, 
including kidney [8, 9]. It has previously been described that Matrilin-2 can interact 
with itself and a variety of matrix molecules including type 1 collagen, fibronectin, and 
laminin and has been postulated to act as an adaptor molecule connecting these 
molecules with other proteins and proteoglycans within the ECM where it may 
regulate ECM homeostasis [7, 10]. Therefore, Matrilin-2 may play an important role in 
DN pathogenesis. 
   Mesangial cells (MCs) located in the intercapillary space that are activated by 
numerous vasoactive substances as well as growth factors. Among various growth 
factors contributing to DN pathogenesis, transforming growth factor-β (TGF-β) is the 
key stimulator of ECM accumulation in the kidney [11]. It has been suggested that 
TGF-β significantly contributes to glomerular filtration barrier alteration, fibrosis and 
sclerosis, which reduce the filtration surface and finally cause glomerular collapse at 
the tubular level[12]. Studies with mouse models of diabetes showed antibodies 
against TGF-β prevented mesangial matrix accumulation [13]. TGF-β exerts its 
biological effects by binding to complexes of type I and II serine/threonine kinase 
receptor that further activates downstream mediators, Smad2 and Smad3 [14]. 
Smad3 is critical for pro-fibrotic effect of TGF-β [15-17] and targeting Smad3 may 
have great therapeutic potential for kidney diseases. Interestingly, recent study 
showed that Matrilin-2 promoter harbored 7 putative Smad-binding sites [18, 19]. In 
this study, therefore, we investigated whether hyperglycemia was able to directly 
stimulate matrilin-2 overexpression and if this process was mediated by the 
TGF-β/Smad 3 pathway by using a mouse mesangial cell line.  
2. Materials and Methods 
2.1 Cell culture 
   Mouse mesangial cells (MMCs) (SV40 MES13) were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD) and maintained in continuous culture 
at 37oC/5% CO2 using DMEM/F-12 containing 5% FBS and 12 mM HEPES (pH 7.0). 
MMCs grown in 100 mm culture dish with similar confluent were incubated with 
serum-free media for 48 hours to synchronize the cell growth. Then, cells were plated 
into 12-well culture dishes for subsequent assays. To assess the expression of 
Matrilin-2 cultured under diabetic conditions, MMCs were grown in high glucose (30 
mM) medium for 24 hours, and harvested for PCR and western blot analysis. For 
TGF-β1 stimulation study, cells were treated with 10ng/ml recombinant TGF-β1 
(PeproTech, Rocky Hill, NJ ), and then were harvested at different time points (12h, 
24h, 48h, and 72h). While for TGF-β1/Smad3 signaling pathway assay either in 
high-glucose or normal condition, cells were pretreated with the indicated amount of 
the specific TGF receptor type I inhibitor SB-431542 (Selleckchem) and Smad3 
inhibitor SIS3 (Billerica MA) for 2 h, followed by stimulation with 10ng/ml TGF-β1 for 
24 h, samples were then measured by Western blotting analysis 
 
2.2 Real-Time PCR  
   Total RNAs were extracted from MMCs using RNeasy Kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. QuantiTect SYBR green PCR Kit 
(Qiagen, Valencia, CA) with DNA Engine Opicon 2 Continuous Fluorescence 
Detection System (MJ Research, Waltham, MA) were used to perform quantitative 
RT-PCR. Primers used in amplification of target genes mRNA were as follows: 
matrilin-2 (forward, 5’-TGCCTCTGAGCCCATTGACAAG-3’; reverse, 
5’-TATGTTGCACTGTTGGCTGGT-3’); 18S RNA (forward, 
5’-CGGCTACCACATCCAAGGAA-3’; reverse, 5’-GCTGGAATTACCGCGGCT-3’). 
The 18S RNA was amplified at the same time and used as an internal control. The 
matrilin-2 mRNA level was normalized to housekeeping gene 18S RNA levels. Then 
the relative value of matrilin-2 mRNA was measured and calculated. 
2.3 Protein extraction and Western Blotting Analysis 
   Western blotting was performed to determine Matrilin-2 protein expression level in 
MMCs under high-glucose condition. Treated cells were harvested and lysed with 
RIPA buffer (Sigma, St. Louis, MO). Protein quantification was performed by BCA 
protein assay (Thermo Scientific, Waltham, MA). Equal amounts of protein (30 
ug/lane) were resolved by 12% SDS-polyacrylamide gels, transferred onto 
nitrocellulose membranes (Invitrogen, Carlsbad, CA), then the membranes were 
blocked with 5% milk in TBST (25 mM Tris–HCl, pH 7.5; 125 mM NaCl; 0.1% Tween 
20), followed by incubation with polyclonal rabbit anti-Matrilin-2 antibody (1:2000, 
NBP1-76328) (Novus Biologicals, Littleton CO) and rabbit anti-β-actin antibody 
(1:3000, 622101) (Biolegend, San Diego, CA) at 4°C overnight, then the bound 
horseradish peroxidase-conjugated secondary antibody was detected using an ECL 
detection system. Protein expression levels were determined by analyzing the signals 
captured on the nitrocellulose membranes using an image analyzer. 
2.4 Statistics 
   Results were presented as the Mean±SD. Paired Student’s t-tests were used for 
statistical analysis, p values less than 0.05 were considered significant. 
3. Results 
3.1 High glucose significantly induced Matrilin-2 expression. 
   To investigate whether Matrilin-2 was involved in DN, we observed the mRNA and 
protein expression levels of Matrilin-2 in SV40 MES 13 cells (MMCs) treated with the 
high concentration of glucose (30mM). Clearly, both Matrilin-2 mRNA and protein 
levels were significantly upregulated in a high glucose condition when comparing to 
normal glucose condition (p<0.05) (Figure 1, A, B, C).  
3.2 Inhibition of TGF-β1 and Smad3 suppressed high-glucose-induced Matrilin-2 
expression.  
   We pre-treated MMCs with the specific TGF type I receptor kinase inhibitor 
SB-431542, followed by stimulation with 24h high glucose treatments. The western 
blot showed that SB-431542 markedly inhibited high glucose-induced Matrilin-2 
expression at 10uM. Additionally, we applied Smad3 specific inhibitor SIS3 to cultured 
cells and demonstrated that SIS3 significantly inhibited high glucose-induced 
Matrilin-2 expression at a concentration of 10uM as well (Figure 2, A, B).   
3.2 TGF-β1 was able to stimulate expression of Matrilin-2 protein at time-dependent 
manner in MMCs 
For further confirmation, we investigated whether TGF-β1 was able to directly 
induce Matrilin-2 expression in MMCs. Semi-quantitative analysis showed that after 
cultured MMCs were treated with 10ng/ml TGF-β1, Matrilin-2 expression was 
markedly induced in a time-dependent manner (Figure 3.A, B). The expression of 
Matrilin-2 was significantly elevated starting at 12h post TGF-β1 treatments (p<0.05) 
and reached to peak value at 24h (p<0.01).  
3.3 TGF-β1/Smad3 inhibitors inhibited TGF-β1-induced Matrilin-2 expression in 
MMCs. 
As expected, both SB-431542 and SIS3 inhibited TGF-β1-induced Matrilin-2 
expression (Figure 4. A, B).  
4. Discussion 
In DN, changes in the ECM such as increased glomerular basement membrane 
thickness and the extracellular matrix of the mesangium expand occur in both type 1 
and type 2 diabetes. The mesangial ECM is the main cause of declining renal function 
in DN provides structural support for the glomerular capillary convolute, connecting 
with the extraglomerular mesangium at the vascular pole and dysregulation of 
cell-matrix signaling plays an important role in DN[2]. It was found that hyperglycemia 
induced TGF-expression in experimental and human diabetes [20, 21]. Previous 
findings have demonstrated that high glucose stimulates TGF-β1 very early through 
its receptor [22, 23]. It was also demonstrated that TGF-bIIR played an important role 
in the progression of diabetic nephropathy through the intracellular Smad signaling 
[24]. Matrilin-2 was proved to be essential adaptor protein for the generation of 
muscle and nerve by TGF-β/Smad signaling pathway [25], although it remained 
unknown whether Matrilin-2 was involved in DN pathogenesis and if the TGF-β1 
played a role in regulating this protein. In this study, we clearly demonstrated that 
Matrilin-2 expression was induced by hyperglycemia and the TGF-β1/Smad3 pathway 
was involved in high glucose-induced Matrilin-2 expression in MMCs. 
Here, the expression levels of Matrilin-2 mRNA and protein were significantly 
increased after MMCs had been treated with high glucose, suggesting that Matrilin-2 
might be involved in the pathogenesis and progression of DN. Our previous study 
demonstrated that Matrilin-2 was mainly expressed in glomerulus, the basement 
membrane of distal convoluted tubule and renal matrix [8], where was the typical 
lesion location in DN. Change of glucose metabolism could therefore activate intra- 
and extracellular signaling pathways leading to abnormal ECM accumulation. This 
was the first time that Matrilin-2 was proved to be upregulated in MMCs under a 
high-glucose condition and our data suggested that Matrilin-2 accumulation might be 
an important damage factor for glomerular fibrosis in DN.  
MMCs, locating in the intercapillary space, are vital for glomerulus to maintain 
normal physiological status. The response of MMCs under hyperglycemia condition is 
highly complex. Besides being exposed to extracellular glycated-proteins, MMCs 
activities are also affected and controlled by intracellular mediators, such as TGF-β1. 
In renal diseases, TGF-β1 is upregulated and stimulates MMCs to produce ECM 
proteins, including type I, III and IV collagen, and laminin, contributing to glomerular 
ECM accumulation [12, 26]. In MMCs, it has been proved that TGF-β1/Smad3 
signaling pathway could stimulates the synthesis and accumulation of ECM, and is 
associated with MMC hypertrophy in diabetes[12]. Here, we demonstrated that 
TGF-β1 and Smad3 mediated high glucose-induced Matrilin-2 activation in MMCs.  
    The biomarkers of tissue fibrosis have been investigated extensively in the 
pathogenesis of DN. Here our study revealed that Matrilin-2 could be induced by high 
glucose in MMCs through the TGF-β1/Smad3 signaling pathway. Our data may 
provide a potential diagnostic and therapeutic target for DN.  
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Figure Legends 
 
Figure 1. High glucose induced mRNA and protein expression of matrilin-2 in 
MMCs. A, PCR results showed that Matrilin-2 mRNA expression levels were 
significantly upregulated when MMCs had been treated with high glucose. B. 
Western blot demonstrated that Matrilin-2 protein bands at 74kD was markedly 
increased by high glucose (30mM) as compared to the control group. C, 
semi-quantitative result showed that Matrilin-2 protein expression levels were 
significantly induced by high glucose as comparing to the control group. 
*p<0.05. 
Figure 2.  
High glucose-induced Matrilin-2 was suppressed by TGF-β1 and Smad3 
inhibitors. A, monolayer MMCs grown in complete growth medium were 
pretreated with specific TGF receptor type I inhibitor, SB-431542 (10uM), and 
Smad3 inhibitor, SIS3 (10 uM), for 2h followed treatments with normal (5mM) 
or high glucose (30mM) for additional 24h. Western blotting analyses were 
then used for Matrinlin-2 quantification. B, ImageJ software analysis showed 
that TGF-β1 and Smad3 inhibitors significantly suppressed high 
glucose-induced Matrilin-2 protein expression. *p<0.05, **p<0.01.   
Figure 3. 
TGF-β1 stimulated Matrilin-2 expression in a time-dependent manner. A, 
MMCs had been treated with 10ng/ml TGF-β1 for the indicated time period. 
The protein levels of Matrilin-2 were measured by using Western blot analyses. 
B, Quantitation analyses showed Matrilin-2 expression levels were induced 
starting at 12h post TGF-β1 treatments and reached to peak value at 24h. *p<0.05, 
**p<0.01. 
Figure 4. TGF-β1 and Smad3 inhibitors suppressed TGF-β1-induced 
Matrilin-2 expression. A. MMCs were pretreated with specific TGF receptor 
type I inhibitor, SB-431542 (10uM), and Smad3 inhibitor, SIS3 (10uM), for 2h, 
followed by treatments with TGF-β1 (10ng/mL) for additional 24h. The 
expression levels of Matrilin-2 were determined by Western blot analyses. B, 
Semi-quantitative analyses by ImageJ showed that TGF-β1 significantly 
stimulated Matrilin-2 protein expression as compared with the control group 
(p<0.05). MMCs pretreated with TGF-β1 and Smad3 inhibitors inhibited 
TGF-β1-induced Matrilin-2 expression (*p<0.05, **p<0.01).   
 
